OUR NEWS - ÉVALUATION ACCÉLÉRÉE

10
Oct

First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service

First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service    For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies. In this study, Pfizer is assessing the effectiveness of a

Read more